A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)

Summary

A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study ,the mean change from baseline in vertex target area hair count (TAHC) after treatment for 24 weeks.

Timeline

Start

2021-12-06

Primary completion

2023-03-07

Completion

2023-05-15

Outcome

Met primary endpoint

paper from baseline in target area hair count was significantly higher at week 24 PMID 40090937 ↗

release “registrational Phase III clinical trial of the Group ’s CU-40102 (topical finasteride spray) conducted in China for the treatment of androgenetic alopecia reached primary endpoint” cutiatx.com ↗

Publications

• Zhou C, Yang B, Zeng H, Xia R, Dang N, Yang Q, Li J, Zhang C, Zhang G, Wei A, Lai W, Yang S, Diao Q, Ding Y, Wu L, Liu L, Jia D, Zhu H, Zhang J. Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study. Chin Med J (Engl). 2026 Apr 5;139(7):1054-1061. doi: 10.1097/CM9.0000000000003495. Epub 2025 Mar 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Finasteride	Small molecule	0.25 %	Topical
Subject	Finasteride	Small molecule	2.275 mg/ml	Topical

Indications